Your session is about to expire
← Back to Search
Other
Memantine for Liver Cancer
Phase 2 & 3
Recruiting
Led By Arthur Winer, MD
Research Sponsored by Inova Health Care Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years from the initial visit
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at the effects of a single med, memantine, on people with advanced liver cancer who cannot have other treatments. We'll measure effects on quality of life too.
Who is the study for?
This trial is for adults over 18 with advanced, inoperable liver cancer (hepatocellular carcinoma) who haven't had intensive systemic therapy. They must have a specific level of cirrhosis (Child-Pugh score B7+), be able to perform daily activities with minimal help, and agree to use contraception if there's any chance of pregnancy.
What is being tested?
The study tests the drug Memantine (Namenda) on patients with liver cancer that can't be removed by surgery. It aims to see how effective the drug is and its impact on quality of life over time. Participants will receive Memantine as a single agent treatment.
What are the potential side effects?
While not specified here, common side effects of Namenda may include dizziness, headache, confusion, constipation. Since it's being tested in people with liver issues, monitoring for worsening liver function or other organ-related problems would also be important.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years from the initial visit
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years from the initial visit
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Patients Progression Free Survival at 6 months
Other study objectives
Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (EORTC QLQ-C30)
Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Arm 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Namenda
2004
N/A
~30
Find a Location
Who is running the clinical trial?
Inova Health Care ServicesLead Sponsor
73 Previous Clinical Trials
22,400 Total Patients Enrolled
Arthur Winer, MDPrincipal InvestigatorInova Health Care Service